China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application (MAA) for Foresee Pharmaceuticals’ Camcevi 42 mg to treat adult patients with advanced prostate cancer.
CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
The US Food and Drug Administration (FDA) has accepted and granted priority review to Pfizer and Astellas Pharma’s supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) to treat non-metastatic castration-sensitive prostate cancer (nmCSPC) patients with high-risk biochemical recurrence (BCR).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.